Testing a new combo therapy for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 3 months, confirmed by a colonoscopy and tissue sample.
- Your UC is moderate to severe based on a score from 5 to 9 on a special scale (may include bleeding and seeing inflammation on a scope).
- You've tried at least one standard treatment (like steroids or immune-modifying pills) that didn't work, stopped working, or caused side effects.
- You have not had mirikizumab before.
- You do not have Crohn's disease, unclassified IBD, or primary sclerosing cholangitis.
- You have not had or need colon surgery, and have no current serious infections or blockages in your bowel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.